Insys Therapeutics Inc., of Phoenix, signed an exclusive sublicense with Gold Coast Therapeutics Inc., of Illinois, to develop a combination of cromolyn sodium and cetirizine (Zyrtec, Johnson & Johnson) as a new chemical entity to treat patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).